Back

prof. dr. J.G.J. (Jan) van de Winkel

prof. dr. J.G.J. (Jan) van de Winkel

Full Professor

Show full profile

Research Output (250)

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder C.A., Beurskens F.J.M., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M.M., Ugurlar D., Rosati S, Heck A.J.R., van de Winkel J.G.J., Wilson I.A., Koster A.J., Taylor R.P., Saphire E.O., Burton D.R., Schuurman J., Gros P., Parren P.W.H.I. 2014, In: Science. 343 , p. 1260-1263 4 p.

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P., Baerenwaldt A., Kellner C., Staudinger M., Dechant M., Stauch M., Beurskens F.J., Parren P.W.H.I., van de Winkel J.G.J., Valerius T., Humpe A., Repp R., Gramatzki M., Nimmerjahn F., Peipp M. 2013, In: Leukemia. 27 , p. 190-201 12 p.

Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions

Stemerding A.M., Kohl J., Pandey M.K., Kuipers A., Leusen J.H.W., Boross P., Nederend M., Vidarsson G., Weersink A.J.L., van de Winkel J.G.J., van Kessel C.P.M., van Strijp J.A.G. 2013, In: Journal of Immunology. 191 , p. 353-362 10 p.

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P., Lohse S., Nederend M., Jansen J.H.M., van Tetering G., Dechant M., Peipp M., Royle L., Liew L.P., Boon L, van Rooijen N., Bleeker W.K., Parren P., van de Winkel J.G.J., Valerius T., Leusen J.H.W. 2013, In: Embo Molecular Medicine. 5 , p. 1213-1216 4 p.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Labrijn A.F., Meesters J., Goeij B.E., van den Bremer E.T.J., Neijssen J., van Kampen M.D., Strumane K., Verploegen S., Kundu A., Gramer M.J., van Berkel P.H.C., van de Winkel J.G.J., Schuurman J., Parren P.W.H.I. 2013, In: Proceedings of the National Academy of Sciences of the United States of America. 110 , p. 5145-5150 6 p.

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C., Maurer T., Hallack D., Repp R., van de Winkel J.G.J., Parren P.W.H.I., Valerius T., Humpe A., Gramatzki M., Peipp M. 2012, In: Journal of Immunology. 189 , p. 5037-5046 10 p.

Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele.

Raaz-Schrauder D., Ekici A.B., Munoz L.E., Klinghammer L., Voll R.E., Leusen J.H.W., van de Winkel J.G.J., Reis A., Schett G., Garlichs C.D., Herrmann M. 2012, In: Autoimmunity. 45 , p. 556-564 9 p.

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

Lohse S., Brunke C., Derer S., Peipp M., Boross P., Kellner C., Beyer T., Dechant M., van de Winkel J.G.J., Leusen J.H.W., Valerius T. 2012, In: Journal of Biological Chemistry. 287 , p. 25139-25150 12 p.

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

Kellner C., Hallack D., Glorius P., Staudinger M., Mohseni Nodehi S., de Weers M., van de Winkel J.G.J., Parren P.W.H.I., Stauch M., Valerius T., Repp R., Humpe A., Gramatzki M., Peipp M. 2012, In: Leukemia. 26 , p. 830-834 5 p.

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.

Otten M.A., Bakema J.E., Tuk C.W., Glennie M.J., Tutt A.L., Beelen R.H., van de Winkel J.G.J., van Egmond M. 2012, In: European Journal of Immunology. 42 , p. 1815-1821 7 p.

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not